Patents by Inventor Matthew Bernett

Matthew Bernett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered IL-2 Fc fusion proteins
    Patent number: 11981717
    Abstract: The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: May 14, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John Desjarlais, Rajat Varma, Rumana Rashid
  • HETERODIMERIC PROTEINS
    Publication number: 20240092871
    Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.
    Type: Application
    Filed: September 7, 2023
    Publication date: March 21, 2024
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • PD-1 targeted IL-15/IL-15R? Fc fusion proteins with improved properties
    Patent number: 11932675
    Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: March 19, 2024
    Assignees: GENENTECH, INC., XENCOR, INC.
    Inventors: John Desjarlais, Matthew Bernett, Michael Hedvat, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Juan Diaz, Patrick Holder, Christine Huang
  • BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3
    Publication number: 20240018234
    Abstract: The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 18, 2024
    Inventors: Matthew BERNETT, Alex NISTHAL, Gregory MOORE
  • Targeted IL-12 heterodimeric Fc-fusion proteins
    Patent number: 11851466
    Abstract: The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: December 26, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Rumana Rashid, Nargess Hassanzadeh-Kiabi, Michael Hedvat
  • OPTIMIZED ANTIBODY VARIABLE REGIONS
    Publication number: 20230399401
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Application
    Filed: June 9, 2023
    Publication date: December 14, 2023
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Bispecific antibodies that bind to CD38 and CD3
    Patent number: 11840579
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: December 12, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Seung Chu, Gregory Moore, John Desjarlais
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20230365717
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 16, 2023
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric proteins
    Patent number: 11814423
    Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: November 14, 2023
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • NOVEL HETERODIMERIC PROTEINS
    Publication number: 20230279154
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Application
    Filed: March 10, 2023
    Publication date: September 7, 2023
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Bispecific binding agents binding to CLDN18.2 and CD3
    Patent number: 11739145
    Abstract: The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: August 29, 2023
    Inventors: Matthew Bernett, Alex Nisthal, Gregory Moore
  • Optimized antibody variable regions
    Patent number: 11718667
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: August 8, 2023
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS
    Publication number: 20230220081
    Abstract: The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: December 13, 2022
    Publication date: July 13, 2023
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
  • IL-12 heterodimeric Fc-fusion proteins
    Patent number: 11655277
    Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: May 23, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
  • BISPECIFIC ANTIBODIES THAT BIND TO B7H3 AND NKG2D
    Publication number: 20230151095
    Abstract: Provided herein are bispecific antibodies that bind to B7H3 and NKG2D (e.g., antibodies having Fab-scFv-Fc, Fab2-scFv-Fc, mAb-scFv and stackFab2-scFv-Fc formats) or antigen binding fragments thereof. Also provided herein are polynucleotide sequences encoding a chain and/or a CDR of a bispecific antibody of the disclosure; and vectors and cells comprising such polynucleotide sequences. Also provided herein are methods of treating cancer in a subject with a bispecific antibody of the disclosure.
    Type: Application
    Filed: November 7, 2022
    Publication date: May 18, 2023
    Inventors: Katrina Bykova, Matthew Faber, Matthew Bernett, Tian Zhang, Erik Pong, Kendra Avery, John Desjarlais
  • BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3
    Publication number: 20230137677
    Abstract: The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Application
    Filed: December 6, 2022
    Publication date: May 4, 2023
    Inventors: Matthew BERNETT, Alex NISTHAL, Gregory MOORE
  • Heterodimeric proteins
    Patent number: 11634506
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: April 25, 2023
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS AND USES IN COMBINATION THERAPIES THEREOF
    Publication number: 20230055445
    Abstract: The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.
    Type: Application
    Filed: June 2, 2022
    Publication date: February 23, 2023
    Inventors: Matthew Bernett, John R. Desjarlais, Michael Hedvat, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Rajat Varma
  • Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments
    Patent number: 11584794
    Abstract: The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: February 21, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
  • BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES
    Publication number: 20230041377
    Abstract: The present invention is directed to heterodimeric anti-LAG-3×anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
    Type: Application
    Filed: September 28, 2022
    Publication date: February 9, 2023
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh S. Muchhal